ZW 209
Alternative Names: ZW-209Latest Information Update: 02 Feb 2026
At a glance
- Originator Zymeworks
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Small cell lung cancer
Most Recent Events
- 12 Jan 2026 ZW 209 is available for licensing as of 12 Jan 2026. www.zymeworks.com
- 25 Apr 2025 Preclinical trials in Small cell lung cancer in Canada (Parenteral), prior to April 2025
- 25 Apr 2025 Efficacy and adverse event data from a preclinical trial in Small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)